Overview

CAR T-cell therapy involves the treatment of cancer by modifying a patient's T-cells in the lab so they will attack cancer cells. CAR T-cell therapy is used to treat certain blood cancers, and it is currently investigated for use in treating other cancer types. If clinical development of the CART T-cell produces the wrong T-cell subtype, patient outcome will suffer.

Manufacturing CAR-T products is time-consuming, costly, highly complicated, and provides little control of the functional potency of the product beyond that of expression of a chimeric T-cell receptor.

 

We are developing cell culture media for T-cell subtype control to improve clinical potency in the individual patient and reduction of variability in outcomes between patients.

 

The data generated by our proprietary HD-DOE™ research and development platform shows that we can control the various cell lineages without a pre-requisite T-cell receptor engagement, which allows the cell to avoid exhaustion during production because if the naïve cell population is broadly activated, it will result in a mixed population of T-cells.

Current Developments

We are developing cell culture media for T-cell subtype control

Our cell culture media will improve clinical potency in the individual patient and reduction of variability in outcomes between patients.

We can control the various cell lineages without a pre-requisite T-cell receptor engagement, which allows the cell to avoid exhaustion during production.

Explore Our Other Cell Therapy Programs

Diabetes

Bone Marrow Failure

Blood Diseases & Disorders

Huntington's Disease

Parkinson's Disease